Evidence map›Paper›PMID 31934281›Full record

ArticleAmerican journal of translational research2019

Transplanted mouse liver stem cells at different stages of differentiation ameliorate concanavalin A-induced acute liver injury by modulating Tregs and Th17 cells in mice.

Shanshan Li, Yanzhen Bi, Quanquan Wang, Manman Xu, Zhenglai Ma, Yonghong Yang, Yongkai Chang, Suling Chen, Derong Liu, Zhongping Duan and 2 more

Open access · greenAbstract read
In one paragraph

Article in American journal of translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Shanshan LiDifficult and Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University Beijing 100069, China.
Yanzhen BiDifficult and Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University Beijing 100069, China.
Quanquan WangDepartment of Neuromuscular Disease, The Third Hospital of Hebei Medical University Shijiazhuang 050000, Hebei, China.
Manman XuDifficult and Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University Beijing 100069, China.
Zhenglai MaDifficult and Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University Beijing 100069, China.
Yonghong YangInstitute of Liver Diseases, Affiliated Hospital of Jining Medical University Jining 272000, Shandong, China.
Yongkai ChangDepartment of Neurosurgery, Fuxing Hospital, Capital Medical University Beijing 100038, China.
Suling ChenDepartment of Infectious Disease, Heping Hospital Affiliated to Changzhi Medical College Changzhi 046000, Shanxi, China.
Derong LiuElyon Biotechnologies Gaithersburg, MD 20879, USA.
Zhongping DuanDifficult and Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University Beijing 100069, China.
Feng HongInstitute of Liver Diseases, Affiliated Hospital of Jining Medical University Jining 272000, Shandong, China.
Yu ChenDifficult and Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University Beijing 100069, China.
Beijing Academy of Artificial Intelligence · CNAffiliated Hospital of Jining Medical University · CNCapital Medical University · CNChangzhi Medical College · CNFyodor Biotechnologies (United States) · USHebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute liver failure (ALF) is a disease with a considerably high mortality rate that still lacks a safe and effective treatment. Transplantation of liver stem cells (LSCs) has been considered to be a promising therapeutic alternative for ALF since LSCs have been shown to be involved in immunomodulation and functional reconstruction of the liver. Our present study evaluated and compared the protective effects of the two mouse LSC lines, YE and R5, as well as those of adult mouse hepatocyte (HC), on concanavalin A (ConA)-induced acute liver injury. YE and R5 cells were analyzed by microscopy, functional assays, and gene expression. We confirmed that YE and R5 cells were undifferentiated cells that had partial hepatocytic functions and a potential to differentiate into hepatocytes. YE cells has characteristics of LSCs at the early stage of differentiation, whereas the differentiation stage of R5 cells was later than that of YE cells. Subsequently, YE, R5, and HC cells were intraperitoneally transplanted into three groups of mice, followed by injection of ConA through the tail vein of each mouse at 12 h later. Blood tests, histology, flow cytometry, and quantitative PCR were then used to evaluate the therapeutic effects of the cell transplantations at 24 h after ConA injections. Compared with that of the ConA control group, YE, R5, and HC cells reduced the expression of alanine transaminase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBIL) in serum and alleviated the degree of hepatic necrosis. Moreover, transplantation of these cells induced more regulatory T cells (Tregs) and less T-helper 17 (Th17) cells in the liver and spleen, and also promoted the expression of forkhead box protein 3 (Foxp3) and interleukin (IL)-10; in contrast, these transplantations induced various degrees of inhibition in the expression of retinoic acid-related orphan receptor γt (RORγt), IL-17A, IL-17F, and tumor necrosis factor-α (TNF-α). The protective effects of YE and R5 cells were significantly stronger than those of HC cells, and YE cells at the earlier differentiation stage than that of R5 cells exhibited the strongest protective effects. These results demonstrate that mouse LSCs at different stages of differentiation alleviate ConA-induced acute liver injury in mice by modulating Tregs, Th17 cells, and cytokine secretion.

Indexed as

Acute liver failurecell transplantationdifferent stages of differentiationmouse liver stem cellsTh17 cellsTregs

Identifiers

PMID31934281
PMCPMC6943453
OpenAlexW3006079394

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.